

Health for Humanity 2020 Goals Progress Scorecard

We achieved significant progress in our final year of reporting against our Health for Humanity 2020 Goals. Specifically, we achieved or exceeded 16 of the 17 targets across the goal focus areas of: providing people with better health access and care, using fewer and smarter resources, and partnering to create a culture of health and well-being. The one target not fully achieved was enrolling suppliers covering 80% of our spend in our Supplier Sustainability Program. This was due to COVID-19 impacts experienced by Johnson & Johnson and by our suppliers.

The following Scorecard provides our final progress made against our 2020 Goals.

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2020 [†]	NOTABLE	STATUS
1. Develop and deliver innovative, lifechanging solutions to address the world's major health challenges.	Expand the database, documenting the effectiveness, efficacy, and safety profile of SIRTURO (bedaquiline) through collaborative efforts to further increase access.	Data from the expanded patient database allowed for publication on effectiveness, efficacy, and safety of SIRTURO in two peer-reviewed journals in 2018.	Target was achieved in 2018.	✓ Achieved
	Collaborate on Phase 3 trials and make regulatory submissions for rilpivirine LA, the first all injectable depot regimen for HIV.	Regulatory submissions were made, and approvals received, for the world's first LA injectable HIV treatment regimen (Janssen's rilpivirine LA with ViiV Healthcare's cabotegravir LA): <ul style="list-style-type: none"> • U.S. Food and Drug Administration (FDA): once-monthly treatment regimen approved January 2021. • European Commission: both the once-monthly and every-two-months treatment regimens approved December 2020. • Health Canada and the Australian Therapeutic Goods Administration also approved both the once-monthly and every-two-months treatment regimens. Regulatory review is ongoing in several other countries around the world.	Target was achieved in 2019.	✓ Achieved

[†] Progress against our Health for Humanity 2020 Goals, and associated data, have been assured by ERM CVS. See [independent assurance statement by ERM CVS](#).

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2020 [‡]	NOTABLE	STATUS
2. Deliver innovative healthcare access and training programs that impact a billion lives in underserved areas. ¹	Produce and donate 1 billion doses of VERMOX (mebendazole) to treat >100 million children per year at risk for intestinal worms.	Over 1 billion doses of VERMOX donated in 52 countries with 512 million children having been targeted or treatment.	Cumulatively more than 1.8 billion doses of VERMOX donated since the start of the program in 2006.	+ Exceeded
	Deliver HIV/AIDS therapy access to a cumulative 130,000 adults and 5,000 children.	Over 149,000 adult patients and over 7,800 pediatric patients ² received access to HIV/AIDS therapy with the branded versions of PREZISTA (darunavir), INTELENCE (etravirine) and EDURANT (rilpivirine).	Continued progress has been made to increase pediatric access to our HIV portfolio in resource-limited settings including through the New Horizons Collaborative (NHC) , a partnership aiming to provide children in 11 countries across sub-Saharan Africa with access to HIV therapies. In 2020, the number of pediatric patients enrolled in the NHC program more than doubled, despite the COVID-19 pandemic.	+ Exceeded
	Deliver access to MDR-TB therapy to a cumulative 200,000 patients, potentially curing ³ 157,000 people ⁴ with MDR-TB of the disease.	315,000 patients received access to MDR-TB therapy with SIRTURO (bedaquiline). For the 315,000 MDR-TB patients provided access since 2016, we expect an estimated 276,000 patients ⁴ will be potentially cured by 2022 based on the 88% cure rate. ³	Between 2016 and 2020, SIRTURO was delivered to 144 countries, including all 30 MDR-TB high burden countries.	+ Exceeded
	Together with partners, train 30,000 skilled birth attendants to assist 6 million births.	Together with partners, trained 74,000 birth attendants, who assisted in 6.2 million births.	Target was achieved in 2019.	+ Exceeded
	Support the delivery of 6 million vision screenings to underserved children and corrective treatments (spectacles) as needed to 100,000 underserved children.	In partnership with Lions Club International, supported delivery of 14.7 million vision screenings and corrective treatments (spectacles) to 145,000 underserved children.	Progress in 2020 is estimated based on delivery of eye screenings and corrective treatments (spectacles) in 2019. Actual 2020 data is available after our Report data collection cut-off date.	+ Exceeded

[‡] Progress against our Health for Humanity 2020 Goals, and associated data, have been assured by ERM CVS. See [independent assurance statement by ERM CVS](#).

¹ “Underserved” refers to populations that are disadvantaged because of ability to pay, ability to access care, ability to access comprehensive healthcare, or other disparities for reasons of race, religion, language.

² In 2020, we revised our calculation methodology utilising best available data from UNAIDS to more accurately reflect all the pediatric patients (within scope of the goal) who have received access to our HIV medicines.

This explains the increase in number of pediatric patients included in our 2020 reporting compared to prior years.

³ The cure rate is 87.8% for patients treated with bedaquiline containing regimens, based on *The Lancet Respiratory Medicine*, Volume 392, September 2018, Pages 821-34.

⁴ As communicated through the product label, SIRTURO is taken for six months as part of a combination therapy with multiple other drugs; in total, a patient often requires up to two years of treatment to be cured.

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2020 [‡]	NOTABLE	STATUS
3. Collaborate with government, nonprofit and private sector to foster new models of health that improve economic well-being and healthcare in key emerging markets.	Activate signature partnerships/initiatives for five of our largest Consumer Health brands to promote the health and well-being of people in need around the world.	In 2020, as part of the World Health Organization Access Initiative for Quitting Tobacco, Johnson & Johnson Consumer Health donated Nicotine Replacement Therapy (NRT) to help smokers who are most vulnerable to COVID-19 and do not have access to NRT and support. In prior years we activated partnerships with BAND-AID® Brand Adhesive Bandages, JOHNSON'S, LISTERINE and STAYFREE.		✓ Achieved
	Drive policy thought leadership and strategic engagements to expand healthcare access and coverage in at least three emerging markets (including Brazil, China and India), and lead three to five pilots to demonstrate the results of these efforts. ⁵	<ul style="list-style-type: none"> • More than 850 engagements conducted with government officials and other partners in Brazil, China, Indonesia, Malaysia, Russia and Rwanda in 2020. • Engagements were completed in Colombia, Mexico, and Philippines. • Existing pilot projects to expand healthcare access and coverage in Brazil, China, Indonesia, Russia and Rwanda continued. • Two new pilots launched in 2020: a project in Uganda focused on advancing pediatric HIV care and a second project in China focused on private health insurance policy. 	While India is still a key market for our policy thought leadership work, we have not consistently highlighted the ongoing efforts in India, aside from a program Johnson & Johnson piloted in 2017. We expanded our reporting to other key emerging markets, including innovative programs in Africa. At the same time, Johnson & Johnson continues to engage with the Indian government to help expand healthcare access and coverage.	✓ Achieved
4. Fully integrate sustainable design solutions into our product innovation processes.	New and existing products representing 20% of Johnson & Johnson revenue achieved EARTHWARDS recognition for sustainable innovation improvements.	New and existing products representing 25% of Johnson & Johnson revenue achieved EARTHWARDS recognition.	Target was achieved in 2019.	+ Exceeded

[‡] Progress against our Health for Humanity 2020 Goals, and associated data, have been assured by ERM CVS. See [independent assurance statement by ERM CVS](#).

⁵ Engagements are defined as contacts made between Johnson & Johnson's Government Affairs & Policy and Global Public Health teams and the governments in each market. Pilots are defined as projects implemented among the population in markets to expand healthcare access and coverage.

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2020 [‡]	NOTABLE	STATUS
4. Fully integrate sustainable design solutions into our product innovation processes.	Increase the recyclability of our Consumer Health product packaging to 90+% (on a weight basis) via design and partnerships in five key markets where mature recycling infrastructure exists (Canada, France, Germany, UK, and U.S). ⁶ In three other markets where recycling infrastructure is less mature engage in partnerships to advance material recovery and recycling efforts.	Successfully established four partnerships to promote recycling in markets where recycling infrastructure is less mature. Continued partnerships with two co-ops in Brazil to advance material recovery and recycling efforts. Successfully concluded one partnership in India as the program transitioned to an Extended Producer Responsibility (EPR) ⁷ model.	The main focus in 2020 was to continue advancing our inclusive recycling model in Brazil by: <ul style="list-style-type: none"> • collaborating with other companies through the Inclusive Waste Recycling Consortium (iWrc). • building and launching a digital marketplace to help provide traceability of recycled materials recovered by social fingerprinted⁸ co-ops as they move through the system. 	✓ Achieved
5. Reduce our impacts on climate and water resources.	Reduce absolute carbon emissions 20% by 2020, and 80% by 2050.	CO ₂ emissions decreased by 45% globally since 2010 (Scope 1 and Scope 2).	Target was achieved in 2019.	+ Exceeded 2020 target
	Produce/procure 35% of electricity from renewable sources by 2020; aspire to power all facilities with renewable energy by 2050.	54% of electricity is produced or procured from renewable energy sources.	Renewable Power Purchase Agreements (PPAs) signed in 2019 for our operations in Belgium, Ireland, Mexico and the Netherlands, as well as green tariff electricity contracts in Germany, Greece and Japan, all took effect in 2019 or early 2020.	+ Exceeded 2020 target
	Conduct a comprehensive water risk assessment at 100% of manufacturing/R&D locations and implement resource protection plans at the high-risk sites.	We completed the comprehensive water risk assessment at 100% of manufacturing/R&D locations in 2016. By the end of 2019, 100% of all high-risk sites developed mitigation plans and budgeted for their implementation. By the end of 2020, 61% of all high-risk sites had completed implementation of mitigation plans and the remaining 29% budgeted for completion in 2021.	Newly acquired sites are assessed within three full calendar years post-acquisition.	✓ Achieved

[‡] Progress against our Health for Humanity 2020 Goals, and associated data, have been assured by ERM CVS. See [independent assurance statement by ERM CVS](#).

⁶ In 2018 Johnson & Johnson Consumer Inc. signed the [New Plastics Economy Global Commitment](#). By joining this global multi-stakeholder initiative, we set a new ambitious 2025 plastics packaging commitment, which supersedes our 2020 target. Progress against the new 2025 commitment is reported in the [Product Sustainability](#) section of this Report

⁷ Extended Producer Responsibility: a model where producers are responsible for the collection and recycling of specified volumes of plastic they produce and place into the market. "Producer" defined as: persons engaged in manufacture or import of carry bags or multilayered packaging or plastic sheets or like, and includes industries or individuals using plastic sheets or like or covers made of plastic sheets or multi-layered packaging for packaging or wrapping the commodity.

⁸ Social fingerprinting is a standardized process developed by Social Accountability International to measure and improve an organization's social performance. See more information [here](#).

GOAL	2020 TARGET	PROGRESS MADE IN 2016-2020 [‡]	NOTABLE	STATUS
6. Collaborate with our suppliers to accelerate environmental and social improvements across the value chain.	Enroll suppliers covering 80% of our spend ⁹ in our Supplier Sustainability Program	Enrolled suppliers covering approximately 74% of spend ¹⁰ in our Supplier Sustainability Program.	The COVID-19 pandemic impacted both Johnson & Johnson's capacity to perform supplier assessments and our suppliers' ability to dedicate time and resources to meet the requirements of our Supplier Sustainability Program. As a result, we were unable to assess, and therefore enroll enough of our supply base to achieve our 2020 target.	↪ Not achieved
	Consistently achieve benchmark spending with U.S. diverse suppliers and small suppliers and double the number of countries with established supplier diversity and inclusion programs. ¹¹	In 2020, diverse supplier spending achieved 11% and small supplier spending achieved 17% of total U.S. spend, continuing to exceed benchmark levels. Our supplier diversity and inclusion programs are now established in a total of 17 countries (the U.S. and 16 others) against the baseline of six.	The 16 countries outside the U.S. where we have started diverse supplier tracking are: Australia, Belgium, Brazil, Canada, China, Colombia, France, Germany, Indonesia, Japan, Mexico, Singapore, South Africa, Spain, Switzerland and UK.	+ Exceeded
7. Empower and engage the Johnson & Johnson family of employees to become the healthiest workforce.	Empower and engage employees toward a "personal best" in health and well-being via: training of at least 100,000 employees in the principles of ENERGY FOR PERFORMANCE; ¹² connecting at least 100,000 employees to their health via innovative digital health tools; and providing access to at least 100,000 employees to both fully implemented ¹³ healthy eating and fully implemented healthy movement cultures.	103,000 ¹² employees have completed the principles of ENERGY FOR PERFORMANCE training since the start of the program. 129,000 employees and 126,000 employees were provided access to 100% implementation of policies for healthy eating and healthy movement cultures, respectively.	The target to connect at least 100,000 employees to their health via innovative digital health tools by 2020 was achieved in 2019.	+ Exceeded

[‡] Progress against our Health for Humanity 2020 Goals, and associated data, have been assured by ERM CVS. See [independent assurance statement by ERM CVS](#).

⁹ Based on spend data from prior calendar year.

¹⁰ Based on spend data from 2018.

¹¹ Represents spend we have control over/addressable spend, which is defined as products and services that procurement teams can negotiate with suppliers to meet business goals.

¹² We count our 28,000 active employees who completed ENERGY FOR PERFORMANCE training prior to January 1, 2016, towards progress against this target.

¹³ Defined as 100% implementation of policies, programs and practices for both healthy eating and healthy movement.